ImClone Systems ( IMCL ) is finally escaping its scandal-plagued past to become biotech's most desirable property, at least for the moment. That may seem odd, given that its sole product on the market—the cancer drug Erbitux—has not lived up to ...
- Recent posts:
- Why All the ImClone Interest? Its Pipeline - BusinessWeek
- New twist in brain obesity riddle - BBC Health
- Diet for Weight Loss
- Your Healthy Slice - NWITimes.com
- Windows wrap house in Harford hunt country - Baltimore Sun
- Decline in Alaskan sea otters affects bald eagles' diet - EurekAlert
- Pasta Salad with Garbanzo Beans, Tomatoes, and Feta Cheese
- Music 'boosts exercise endurance' - BBC Health
- U.S. Territories Defend Bailout's $192M Tax Break on Rum - FOX News
- Reporter fired over pro-Obama T-shirt - Detroit News
- Why Most Weight Loss Diets Don’t Work
- Does Weight Loss Without Exercise Make Sense
- Dismissal came as a surprise to former Tigers coach Hernandez - Detroit News
- Ig Nobel prizes: Awards showcase humorous side of research - Boston Globe
- World's fattest man to wed after massive diet - ABS-CBN
- Terror, inflation may dampen N-celebrations - Times of India
- Candidates' Health Plans: Healthy Impact?
- 2008-09 Team Preview: Nashville Predators - ESPN.com
- Roads unhealthy for exercise - Detroit News
- 7 Diet Tips to Lose Weight